Aarkstore Enterprise InDex Pharmaceuticals AB – Product Pipeline Review – H2 2011

http://www.aarkstore.com/categories/index.asp




InDex Pharmaceuticals AB – Product Pipeline Review – H2 2011


InDex Pharmaceuticals AB – Product Pipeline Review – H2 2011

Summary

Global Market Direct pharmaceuticals report, “InDex Pharmaceuticals AB - Product Pipeline Review - H2 2011” provides data on the InDex Pharmaceuticals AB research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct proprietary databases, InDex Pharmaceuticals AB corporate website, SEC filings, investor presentations and featured press releases, both from InDex Pharmaceuticals AB and industry-specific third party sources, put together by Global Markets Direct team.

Scope

- InDex Pharmaceuticals AB - Brief InDex Pharmaceuticals AB overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of InDex Pharmaceuticals AB human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of InDex Pharmaceuticals AB with complete description of the product developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the InDex Pharmaceuticals AB pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate InDex Pharmaceuticals AB strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of InDex Pharmaceuticals AB in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the InDex Pharmaceuticals AB R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with InDex Pharmaceuticals AB.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of InDex Pharmaceuticals AB and identify potential opportunities in those areas.

For more information, please visit :-

Marketing Team
Aarkstore Enterprise
Phone:08149852585
Email:enquiry@aarkstore.com
URL:www.aarkstore.com
http://twitter.com/aarkstoredotcom
http://in.linkedin.com/in/aarkstore
http://www.facebook.com/aarkstoreenterprise

http://www.aarkstore.com/reports/InDex-Pharmaceuticals-AB-Product-Pipeline-Review-H2-2011-161724.html


More Related Reports :-

http://www.aarkstore.com/search/viewresults.asp?search=Pipeline%20Review,%20H2%202011&PubId=&pagenum=1
Argos Therapeutics, Inc. – Product Pipeline Review – H2 2011
Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2011
Hemispherx Biopharma, Inc. – Product Pipeline Review – H2 2011
Rosacea - Pipeline Review, H2 2011
IMMD Inc. – Product Pipeline Review – H2 2011
Macular Edema - Pipeline Review, H2 2011
InDex Pharmaceuticals AB – Product Pipeline Review – H2 2011
Pouchitis - Pipeline Review, H2 2011
Friedreich Ataxia - Pipeline Review, H2 2011
PharmaEssentia Corporation – Product Pipeline Review – H2 2011
Osteopenia - Pipeline Review, H2 2011
Physica Pharma – Product Pipeline Review – H2 2011

Was this helpful? 0 0 Comments

You're reading Aarkstore Enterprise InDex Pharmaceuticals AB – Product Pipeline Review – H2 2011.